Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

November 30, 2006

Study Completion Date

March 31, 2012

Conditions
Breast Cancer
Interventions
DRUG

Herceptin

Given intravenously once weekly for 12 weeks prior to surgery.

DRUG

Taxol

Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.

DRUG

Adriamycin

Given every three weeks for 12 weeks after surgery.

DRUG

Cytoxan

Given every three weeks for 12 weeks after surgery.

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Harvard Vanguard Medical Associates

OTHER

collaborator

Brigham and Women's Hospital

OTHER

lead

Harold J. Burstein, MD, PhD

OTHER